EGFR and cancer: Soluble ectodomains of LRIG1 are reportedly sufficient to inhibit the growth of cancer cells by attenuating EGFR activity [27], and more recently, a study showed that the LRIG1 ectodomain can be naturally shed and can function as a non-cell-autonomous regulator of EGFR signaling [31].